As a refresher, here is the CONX-BGMD PR news from last month:
Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM)
Corgenix to manufacture BG Medicine's novel biomarker test in microtiter ELISA format
December 14, 2009, 9:15 am EST
DENVER, Dec. 14 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, and BG Medicine, Inc. (BGM), a Waltham, Massachusetts-based life sciences company, announced today a supply agreement whereby Corgenix will manufacture BGM Galectin-3 diagnostic products in enzyme-linked immunosorbent assay (ELISA) microtiter format exclusively for BG Medicine. BG Medicine is seeking regulatory clearance in the United States of the BGM Galectin-3 kit for clinical use in patients with heart failure.
Galectins are a family of proteins that play an important role in organ fibrosis, and galectin-3 has been shown to play an important role in the development and progression of heart failure in animal and human studies. Heart failure is a common, complex, and serious medical condition that affects approximately six (6) million people in the U.S. alone. Once diagnosed, the prognosis is poor, with approximately 50% surviving for more than five years.
"We are extremely pleased to extend our collaboration with BG Medicine to include the manufacturing of the BGM Galectin-3 kit," said Douglass Simpson, Corgenix President and Chief Executive Officer. "BG Medicine is bringing cutting edge technology and science to the cardiology market and we look forward to a long-term relationship."
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases, and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at www.corgenix.com.
About BG Medicine
BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel molecular diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. BG Medicine discovers biomarkers and is developing its diagnostic product candidates using its proprietary, versatile, and scalable technology platform which integrates and automates the precise measurement, analysis, characterization and interpretation of proteins and metabolites collected from bodily fluids. For more information about BG Medicine, see www.bg-medicine.com.
Market Data 
Markets 
AI
